<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Ospedale Maggiore Policlinico, [3], grid.414818.00000 0004 1757 8749Neuromuscular and Rare" exact="Diseases" post="Unit, Foundation IRCCS Caâ€™ Granda Ospedale Maggiore Policlinico, epub:"/>
 <result pre="(NMD) patients. The risk of a severe course of SARS-CoV-2" exact="infection" post="is increased in all but the mildest forms of"/>
 <result pre="oropharyngeal weakness and risk of worsening with fever, fasting or" exact="infection" post="Isolation requirements may have an impact on treatment regimens"/>
 <result pre="immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2" exact="infection" post="under investigation impair neuromuscular function significantly; chloroquine and azithromycin"/>
 <result pre="neuromuscular function significantly; chloroquine and azithromycin are not recommended in" exact="myasthenia gravis" post="without available ventilatory support and prolonged prone positioning may"/>
 <result pre="NMDs (metabolic, mitochondrial, myotonic diseases) and experimental approaches for Coronavirus" exact="disease" post="2019 may be offered â€œcompassionatelyâ€� only after consulting the"/>
 <result pre="support Introduction Since the end of December 2019, the severe" exact="acute" post="respiratory syndrome virus 2 (SARS-CoV-2) pandemic has claimed the"/>
 <result pre="Introduction Since the end of December 2019, the severe acute" exact="respiratory" post="syndrome virus 2 (SARS-CoV-2) pandemic has claimed the lives"/>
 <result pre="Since the end of December 2019, the severe acute respiratory" exact="syndrome" post="virus 2 (SARS-CoV-2) pandemic has claimed the lives of"/>
 <result pre="lives of more than 400,000 individuals worldwide (https://coronavirus.jhu.edu/map.html). Symptomatic SARS-CoV-2" exact="infection" post="causes a wide spectrum of symptoms (referred to as"/>
 <result pre="causes a wide spectrum of symptoms (referred to as â€œCoronavirus" exact="Disease" post="2019â€�, COVID-19), such as fever, dry cough, and fatigue"/>
 <result pre="as fever, dry cough, and fatigue in milder cases and" exact="systemic" post="manifestations in severe disease courses (Fig.Â 1). In parallel,"/>
 <result pre="and fatigue in milder cases and systemic manifestations in severe" exact="disease" post="courses (Fig.Â 1). In parallel, SARS-CoV-2 infection poses a"/>
 <result pre="manifestations in severe disease courses (Fig.Â 1). In parallel, SARS-CoV-2" exact="infection" post="poses a greater risk for old, oncologic, and immunosuppressed"/>
 <result pre="oncologic, and immunosuppressed patients, which also include many individuals with" exact="hereditary" post="and acquired neuromuscular disorders (NMD) that may already present"/>
 <result pre="immunosuppressed patients, which also include many individuals with hereditary and" exact="acquired" post="neuromuscular disorders (NMD) that may already present increased risks"/>
 <result pre="that may already present increased risks due to the underlying" exact="disease" post="(see â€œRisk assessment and stratificationâ€� section). As already reported"/>
 <result pre="may help the neurologic community facing common challenges. Fig. 1" exact="Systemic" post="involvement in SARS-CoV-2 infection. The figure shows the different"/>
 <result pre="different organs and systems possibly involved in coronavirus disease-19 (COVID-19)" exact="infection" post="and it summarizes some pathophysiological and clinical-related features. The"/>
 <result pre="features. The virus can spread beyond the lungs and the" exact="respiratory" post="tract, affecting the gastrointestinal, cardiovascular, renal, and nervous system."/>
 <result pre="different general recommendations for NMD patients are available (e.g. World" exact="Muscle" post="Society), but the literature on the management of non-infected"/>
 <result pre="(ICU), but it poses additional risks for NMD patients with" exact="bulbar" post="involvement; (3) neuromuscular disorders centres should reorganize to offer"/>
 <result pre="neuromuscular disorders will probably encounter. The NMD patient without SARS-CoV-2" exact="infection" post="Risk assessment and stratification Risk assessment and stratification are"/>
 <result pre="and families and their physicians to prevent and manage SARS-CoV-2" exact="infection" post="in this category [6â€&quot;9]. Overall, these documents recognize that"/>
 <result pre="associated with high or very high risk include weakness of" exact="respiratory" post="muscles with a reduction of respiratory volumes, use of"/>
 <result pre="risk include weakness of respiratory muscles with a reduction of" exact="respiratory" post="volumes, use of invasive or non-invasive ventilation devices, oropharyngeal"/>
 <result pre="risk of developing severe COVID-19 complications Muscular weakness of the" exact="chest" post="and/or diaphragm, resulting in respiratory volumes less than 60%"/>
 <result pre="complications Muscular weakness of the chest and/or diaphragm, resulting in" exact="respiratory" post="volumes less than 60% predicted Use of non-invasive or"/>
 <result pre="tracheostomy Presence of dysphagia and oropharyngeal weakness (reduced airway clearance)" exact="Primary" post="cardiac involvement Risk of deterioration with fever, fasting or"/>
 <result pre="Primary cardiac involvement Risk of deterioration with fever, fasting or" exact="infection" post="Risk of rhabdomyolysis with fever, fasting or infection Concomitant"/>
 <result pre="Risk of deterioration with fever, fasting or infection Risk of" exact="rhabdomyolysis" post="with fever, fasting or infection Concomitant diabetes, obesity, neoplastic"/>
 <result pre="fasting or infection Risk of rhabdomyolysis with fever, fasting or" exact="infection" post="Concomitant diabetes, obesity, neoplastic diseases, severe cerebrovascular diseases or"/>
 <result pre="Concomitant diabetes, obesity, neoplastic diseases, severe cerebrovascular diseases or severe" exact="heart" post="diseases (heart failure, ischemic heart disease) Some conditions, such"/>
 <result pre="severe cerebrovascular diseases or severe heart diseases (heart failure, ischemic" exact="heart" post="disease) Some conditions, such as mitochondrial diseases, metabolic myopathies"/>
 <result pre="disease) Some conditions, such as mitochondrial diseases, metabolic myopathies and" exact="myasthenia gravis," post="might also determine a worse outcome because of the"/>
 <result pre="a worse outcome because of the risk of deterioration or" exact="rhabdomyolysis" post="[10] secondary to fever and infections. In addition, patients"/>
 <result pre="outcome because of the risk of deterioration or rhabdomyolysis [10]" exact="secondary" post="to fever and infections. In addition, patients receiving steroid"/>
 <result pre="infections. In addition, patients receiving steroid treatment might undergo an" exact="adrenal crisis" post="during fever or infection if steroid dosage is not"/>
 <result pre="steroid treatment might undergo an adrenal crisis during fever or" exact="infection" post="if steroid dosage is not adjusted [11]. Patients with"/>
 <result pre="not adjusted [11]. Patients with conditions that do not affect" exact="respiratory" post="and swallowing functions and whose immunocompetence is not affected"/>
 <result pre="Additional risk factors increasing the risk of developing severe COVID-19" exact="disease" post="Kyphoscoliosis Highly-active immune-mediated neuromuscular disease Mild respiratory muscle weakness"/>
 <result pre="the risk of developing severe COVID-19 disease Kyphoscoliosis Highly-active immune-mediated" exact="neuromuscular disease" post="Mild respiratory muscle weakness Other medical comorbidities: â€¢ Pulmonary"/>
 <result pre="risk of developing severe COVID-19 disease Kyphoscoliosis Highly-active immune-mediated neuromuscular" exact="disease" post="Mild respiratory muscle weakness Other medical comorbidities: â€¢ Pulmonary"/>
 <result pre="developing severe COVID-19 disease Kyphoscoliosis Highly-active immune-mediated neuromuscular disease Mild" exact="respiratory" post="muscle weakness Other medical comorbidities: â€¢ Pulmonary diseases â€¢"/>
 <result pre="severe COVID-19 disease Kyphoscoliosis Highly-active immune-mediated neuromuscular disease Mild respiratory" exact="muscle" post="weakness Other medical comorbidities: â€¢ Pulmonary diseases â€¢ Liver"/>
 <result pre="neuromuscular disease Mild respiratory muscle weakness Other medical comorbidities: â€¢" exact="Pulmonary" post="diseases â€¢ Liver diseases â€¢ Neutropenia/lymphopenia â€¢ Renal diseases/impairment"/>
 <result pre="comorbidities: â€¢ Pulmonary diseases â€¢ Liver diseases â€¢ Neutropenia/lymphopenia â€¢" exact="Renal" post="diseases/impairment Older age Pregnancy (possible) Concomitant additional neurologic diseases"/>
 <result pre="â€¢ Liver diseases â€¢ Neutropenia/lymphopenia â€¢ Renal diseases/impairment Older age" exact="Pregnancy" post="(possible) Concomitant additional neurologic diseases Dependence from caregivers in"/>
 <result pre="severe complications should follow general rules outlined in the World" exact="Muscle" post="Society (WMS) guidelines [8]. Conversely, high-risk patients should be"/>
 <result pre="hospital facilities and outpatient services to address new patientsâ€™ needs." exact="Local" post="differences in response have depended mainly upon geographical localization"/>
 <result pre="by the authorities), the shortage of PPE and the increased" exact="infection" post="risk for patients imposed consistent changes in the management"/>
 <result pre="virtual encounters. Other services, such as electrodiagnostic tests, muscle, and" exact="nerve" post="biopsies, were suspended unless urgent cases required further evaluations"/>
 <result pre="urgent cases required further evaluations (such as new diagnosis of" exact="amyotrophic lateral sclerosis," post="myasthenia, myositis, or immune-mediated neuropathies). Ancillary services needed reorganization"/>
 <result pre="cases required further evaluations (such as new diagnosis of amyotrophic" exact="lateral sclerosis," post="myasthenia, myositis, or immune-mediated neuropathies). Ancillary services needed reorganization"/>
 <result pre="immune-mediated neuropathies). Ancillary services needed reorganization of personnel and resources:" exact="pulmonary" post="assessments were stopped due to increased risk of viral"/>
 <result pre="resources: pulmonary assessments were stopped due to increased risk of" exact="viral" post="shedding from tested patients; tests for dysphagia were performed"/>
 <result pre="the pandemic, such as adults older than 65, immunocompromised, and" exact="cancer" post="patients (e.g. https://www.esmo.org/for-patients/patient-guides/cancer-care-during-the-covid-19-pandemic) (Tables 1 and 2). NMD patients"/>
 <result pre="performed as much as possible with virtual platforms, such as" exact="pulmonary" post="assessments, fluoroscopic swallowing studies, and neuropsychological evaluations, and outpatient"/>
 <result pre="to quickly identify NMD patients who suffered from severe SARS-CoV-2" exact="infection" post="in other regions/states of the country and promptly manage"/>
 <result pre="of the country and promptly manage possible complicationsâ€&quot;such as ventilation-associated" exact="pulmonary" post="damage, critical-illness myopathies, and neuropathies and emerging COVID-related neurologic"/>
 <result pre="different studies assessing the use of teleneurologyâ€&quot;including telerehabilitationâ€&quot;for patients with" exact="chronic" post="neurologic conditions exist [22, 23], the available literature on"/>
 <result pre="addition, virtual approaches seem to reduce emergency room access and" exact="acute" post="hospitalizations in ALS [28]. Telehealth services for the initial"/>
 <result pre="study based on a small cohort (nâ€‰=â€‰4) of patients with" exact="facioscapulohumeral muscular dystrophy" post="suggested that this approach is considered acceptable by patients"/>
 <result pre="based on a small cohort (nâ€‰=â€‰4) of patients with facioscapulohumeral" exact="muscular dystrophy" post="suggested that this approach is considered acceptable by patients"/>
 <result pre="The use of remote neurologic examination requires adaptation and inventiveness." exact="Muscle" post="strength might be evaluated by movement against gravity, assessed"/>
 <result pre="a neurologic examination at-distance comprises a suspected diagnosis of SARS-CoV-2" exact="infection" post="in a young patient with Charcotâ€&quot;Marieâ€&quot;Tooth polyneuropathy undergoing post-surgical"/>
 <result pre="diagnosis of SARS-CoV-2 infection in a young patient with Charcotâ€&quot;Marieâ€&quot;Tooth" exact="polyneuropathy" post="undergoing post-surgical telerehabilitation sessions [36]. Disease and non-disease-specific scales"/>
 <result pre="young patient with Charcotâ€&quot;Marieâ€&quot;Tooth polyneuropathy undergoing post-surgical telerehabilitation sessions [36]." exact="Disease" post="and non-disease-specific scales have been proposed for patients with"/>
 <result pre="with NMD. Particularly, Revised ALS Functional Rating Scale (ALSFRS-R) for" exact="amyotrophic lateral sclerosis" post="and Myasthenia Gravis Activities of Daily Life (MG-ADL) for"/>
 <result pre="NMD. Particularly, Revised ALS Functional Rating Scale (ALSFRS-R) for amyotrophic" exact="lateral sclerosis" post="and Myasthenia Gravis Activities of Daily Life (MG-ADL) for"/>
 <result pre="ALS Functional Rating Scale (ALSFRS-R) for amyotrophic lateral sclerosis and" exact="Myasthenia Gravis" post="Activities of Daily Life (MG-ADL) for myasthenia gravis are"/>
 <result pre="sclerosis and Myasthenia Gravis Activities of Daily Life (MG-ADL) for" exact="myasthenia gravis" post="are validated, disease-specific scales potentially useful for remote evaluations."/>
 <result pre="Disease-modifying therapies Different expert panels [38] and international societies (e.g." exact="Muscle" post="Dystrophy Society) have already provided general recommendations regarding disease-modifying"/>
 <result pre="used in NMD patients that may increase the risk of" exact="infection" post="or a more severe disease course. As a general"/>
 <result pre="may increase the risk of infection or a more severe" exact="disease" post="course. As a general rule, NMD patients should continue"/>
 <result pre="EMA approved drugs, such as enzymatic replacement therapy (ERT) for" exact="Pompe disease," post="antisense oligonucleotides (ASO) for Duchenne Muscular Dystrophy (DMD) patients"/>
 <result pre="replacement therapy (ERT) for Pompe disease, antisense oligonucleotides (ASO) for" exact="Duchenne Muscular Dystrophy" post="(DMD) patients with deletions amenable to exon 51 skipping,"/>
 <result pre="therapy (ERT) for Pompe disease, antisense oligonucleotides (ASO) for Duchenne" exact="Muscular Dystrophy" post="(DMD) patients with deletions amenable to exon 51 skipping,"/>
 <result pre="to exon 51 skipping, splicing-modulator ASO and gene therapy for" exact="Spinal Muscular Atrophy" post="(SMA), and messenger-RNA interfering molecules for transthyretin (TTR) amyloidotic"/>
 <result pre="exon 51 skipping, splicing-modulator ASO and gene therapy for Spinal" exact="Muscular Atrophy" post="(SMA), and messenger-RNA interfering molecules for transthyretin (TTR) amyloidotic"/>
 <result pre="within the highly specialised setting required for their administration, involving" exact="recurrent" post="visits to hospital tertiary centres, rather than within specific"/>
 <result pre="which immunosuppressive drugs can contribute to severe forms of SARS-CoV-2" exact="infection" post="is still unclear. Depending on the regional pandemic burden,"/>
 <result pre="Fc receptor antagonists (efgatirgimod, currently tested in clinical trials for" exact="myasthenia gravis" post="(MG)) [40] may increase the risk of infection or"/>
 <result pre="for myasthenia gravis (MG)) [40] may increase the risk of" exact="infection" post="or a severe disease course. Immunomodulant therapies currently used"/>
 <result pre="[40] may increase the risk of infection or a severe" exact="disease" post="course. Immunomodulant therapies currently used in NMD patients may"/>
 <result pre="may help against SARS-CoV-2 infection. Some severe SARS-CoV-2 cases with" exact="acute" post="respiratory insufficiency may be associated with complex immune dysregulation"/>
 <result pre="help against SARS-CoV-2 infection. Some severe SARS-CoV-2 cases with acute" exact="respiratory" post="insufficiency may be associated with complex immune dysregulation and"/>
 <result pre="and extending refill periods [42]. The NMD patient with SARS-CoV-2" exact="infection" post="SARS-CoV-2 infection in NMD patients Clinical syndromes associated with"/>
 <result pre="refill periods [42]. The NMD patient with SARS-CoV-2 infection SARS-CoV-2" exact="infection" post="in NMD patients Clinical syndromes associated with SARS-CoV-2 infection"/>
 <result pre="SARS-CoV-2 infection in NMD patients Clinical syndromes associated with SARS-CoV-2" exact="infection" post="have been classified by the World Health Organization (WHO)"/>
 <result pre="Health Organization (WHO) as uncomplicated disease, mild pneumonia, severe pneumonia," exact="acute" post="respiratory distress syndrome (ARDS), sepsis, and septic shock [7]."/>
 <result pre="Organization (WHO) as uncomplicated disease, mild pneumonia, severe pneumonia, acute" exact="respiratory" post="distress syndrome (ARDS), sepsis, and septic shock [7]. In"/>
 <result pre="as uncomplicated disease, mild pneumonia, severe pneumonia, acute respiratory distress" exact="syndrome" post="(ARDS), sepsis, and septic shock [7]. In case of"/>
 <result pre="pneumonia, severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and" exact="septic shock" post="[7]. In case of symptoms suggestive for SARS-CoV-2 infection,"/>
 <result pre="[8, 38]. Most patients affected with COVID-19 have a mild" exact="disease" post="course and should continue the current best practice standard"/>
 <result pre="individualized according to the severity of infection, the risk for" exact="disease" post="exacerbation, and the intensity of immunosuppression [38]. Inpatient admission"/>
 <result pre="[8]. Indeed, patients with baseline reduction of breathing capacity and" exact="pulmonary" post="volumes are especially at risk of rapid worsening of"/>
 <result pre="the disease. We suggest preparing an Emergency card stating specific" exact="respiratory" post="and treatment needs of the single patient, including settings"/>
 <result pre="patients, the NMD specialist should establish a close collaboration with" exact="respiratory" post="and intensive care specialists. As there is great variability"/>
 <result pre="variability among NMD patients in terms of prognosis, treatability, and" exact="disease" post="stage, these patients should not be denied life-saving treatments"/>
 <result pre="not promptly available, the French Rare Health Care for Neuromuscular" exact="Disorders" post="Network developed a list of neuromuscular diseases usually carrying"/>
 <result pre="admission [45]. Conditions with a good prognosis for recovery include" exact="autoimmune" post="and congenital myasthenia, metabolic myopathies, inflammatory myopathies without severe"/>
 <result pre="Conditions with a good prognosis for recovery include autoimmune and" exact="congenital" post="myasthenia, metabolic myopathies, inflammatory myopathies without severe systemic damage"/>
 <result pre="autoimmune and congenital myasthenia, metabolic myopathies, inflammatory myopathies without severe" exact="systemic" post="damage (in particular, pulmonary fibrosis), muscle channelopathies, and most"/>
 <result pre="metabolic myopathies, inflammatory myopathies without severe systemic damage (in particular," exact="pulmonary" post="fibrosis), muscle channelopathies, and most neuropathies, hereditary or acquired"/>
 <result pre="inflammatory myopathies without severe systemic damage (in particular, pulmonary fibrosis)," exact="muscle" post="channelopathies, and most neuropathies, hereditary or acquired [45]. The"/>
 <result pre="damage (in particular, pulmonary fibrosis), muscle channelopathies, and most neuropathies," exact="hereditary" post="or acquired [45]. The positive criteria for a good"/>
 <result pre="particular, pulmonary fibrosis), muscle channelopathies, and most neuropathies, hereditary or" exact="acquired" post="[45]. The positive criteria for a good prognosis for"/>
 <result pre="intensive care in these patients are no major cardiac or" exact="respiratory" post="damage and no major disability. For other patients, the"/>
 <result pre="of resuscitation/ICU admission are [45]: Neuromuscular pathologies with slight progression" exact="Respiratory" post="functions being minimally impaired and stabilized Mild and stabilized"/>
 <result pre="Respiratory functions being minimally impaired and stabilized Mild and stabilized" exact="heart" post="disease Absence of severe thoracic deformities/severe contractures preventing ventral"/>
 <result pre="functions being minimally impaired and stabilized Mild and stabilized heart" exact="disease" post="Absence of severe thoracic deformities/severe contractures preventing ventral decubitus"/>
 <result pre="being minimally impaired and stabilized Mild and stabilized heart disease" exact="Absence of" post="severe thoracic deformities/severe contractures preventing ventral decubitus Absence of"/>
 <result pre="disease Absence of severe thoracic deformities/severe contractures preventing ventral decubitus" exact="Absence of" post="multisystemic impairment and comorbidities Preservation of autonomy for everyday"/>
 <result pre="and intubation, and, if necessary, to write them down beforehand." exact="Limited" post="literature exists on the clinical course and recovery of"/>
 <result pre="series of 5 immunosuppressed MG patients showed high variability of" exact="disease" post="severity and outcome [46]. Three of them developed severe"/>
 <result pre="disease severity and outcome [46]. Three of them developed severe" exact="respiratory" post="insufficiency following the infection and required intubation or high-flow"/>
 <result pre="[46]. Three of them developed severe respiratory insufficiency following the" exact="infection" post="and required intubation or high-flow oxygen, whereas two had"/>
 <result pre="required intubation or high-flow oxygen, whereas two had a milder" exact="disease" post="course. Four of them had a favourable outcome. Indications"/>
 <result pre="Indications of therapy discontinuation in immunosuppressed MG patients during the" exact="infection" post="are uncertain [38]. Although this patient population lacks a"/>
 <result pre="two patients without experiencing a subsequent flair of the underlying" exact="disease" post="after recovery [46]. In some MG patients, SARS-CoV-2 pulmonary"/>
 <result pre="underlying disease after recovery [46]. In some MG patients, SARS-CoV-2" exact="pulmonary" post="infection may directly induce an MG crisis [46, 47]."/>
 <result pre="disease after recovery [46]. In some MG patients, SARS-CoV-2 pulmonary" exact="infection" post="may directly induce an MG crisis [46, 47]. Oxygen"/>
 <result pre="ventilatory support WHO recommends that all patients with SARS-CoV-2 severe" exact="acute" post="respiratory infection (SARI) are started immediately with supplemental oxygen"/>
 <result pre="support WHO recommends that all patients with SARS-CoV-2 severe acute" exact="respiratory" post="infection (SARI) are started immediately with supplemental oxygen therapy"/>
 <result pre="WHO recommends that all patients with SARS-CoV-2 severe acute respiratory" exact="infection" post="(SARI) are started immediately with supplemental oxygen therapy at"/>
 <result pre="lead to pump failure due to exhaustion and weakness of" exact="respiratory" post="muscles, even in previously compensated patients, and hypercapnia may"/>
 <result pre="muscles, even in previously compensated patients, and hypercapnia may worsen" exact="disease" post="course. Hypercapnia is not a classic feature of SARS-CoV-2"/>
 <result pre="SARS-CoV-2 pneumonia, and its appearance might signal the onset of" exact="respiratory" post="muscle weakness [7]. Furthermore, extensive interstitial pneumonia or acute"/>
 <result pre="pneumonia, and its appearance might signal the onset of respiratory" exact="muscle" post="weakness [7]. Furthermore, extensive interstitial pneumonia or acute respiratory"/>
 <result pre="the onset of respiratory muscle weakness [7]. Furthermore, extensive interstitial" exact="pneumonia" post="or acute respiratory distress syndrome (ARDS) usually does not"/>
 <result pre="of respiratory muscle weakness [7]. Furthermore, extensive interstitial pneumonia or" exact="acute" post="respiratory distress syndrome (ARDS) usually does not respond to"/>
 <result pre="respiratory muscle weakness [7]. Furthermore, extensive interstitial pneumonia or acute" exact="respiratory" post="distress syndrome (ARDS) usually does not respond to oxygen"/>
 <result pre="weakness [7]. Furthermore, extensive interstitial pneumonia or acute respiratory distress" exact="syndrome" post="(ARDS) usually does not respond to oxygen therapy alone,"/>
 <result pre="via a face mask with reservoir bag, as a hypoxemic" exact="respiratory" post="failure in ARDS is usually the result of intrapulmonary"/>
 <result pre="mismatch or shunt and therefore requires mechanical ventilation [7]. Indeed," exact="acute" post="hypoxemic respiratory failure requiring respiratory support was the main"/>
 <result pre="shunt and therefore requires mechanical ventilation [7]. Indeed, acute hypoxemic" exact="respiratory" post="failure requiring respiratory support was the main reason for"/>
 <result pre="requires mechanical ventilation [7]. Indeed, acute hypoxemic respiratory failure requiring" exact="respiratory" post="support was the main reason for ICU admittance in"/>
 <result pre="and 11% [48]. As regards NIV, data on Middle East" exact="Respiratory" post="Syndrome (MERS) patients suggest a high failure rate [53]."/>
 <result pre="11% [48]. As regards NIV, data on Middle East Respiratory" exact="Syndrome" post="(MERS) patients suggest a high failure rate [53]. Moreover,"/>
 <result pre="the risk of widespread diffusion of exhaled air and airborne" exact="viral" post="transmission, although recent reports show that newer systems with"/>
 <result pre="setting, with the possibility of rapid ETI in case of" exact="acute" post="deterioration or lack of improvement [7]. ETI and mechanical"/>
 <result pre="the mainstay of treatment for unstable patients with ARDS and" exact="acute" post="respiratory insufficiency. High levels of PEEP are generally required"/>
 <result pre="mainstay of treatment for unstable patients with ARDS and acute" exact="respiratory" post="insufficiency. High levels of PEEP are generally required in"/>
 <result pre="and the presence of comorbidities [56]. In some cases, the" exact="atrophy" post="of masticatory muscles and limited mobility of the cervical"/>
 <result pre="[56]. In some cases, the atrophy of masticatory muscles and" exact="limited" post="mobility of the cervical spine may complicate ETI procedure"/>
 <result pre="atrophy of masticatory muscles and limited mobility of the cervical" exact="spine" post="may complicate ETI procedure [57]. In these cases, intubation"/>
 <result pre="of side effects from neuromuscular blockers and anaesthetic agents. Depolarizing" exact="muscle" post="relaxants (succinylcholine) are contraindicated in NMDs because of the"/>
 <result pre="in NMDs because of the risk of fatal hyperkalemia and" exact="rhabdomyolysis" post="[59]. Non-depolarizing muscle relaxants (e.g. rocuronium, rapacuronium, atracurium) should"/>
 <result pre="of the risk of fatal hyperkalemia and rhabdomyolysis [59]. Non-depolarizing" exact="muscle" post="relaxants (e.g. rocuronium, rapacuronium, atracurium) should be used with"/>
 <result pre="and careful titration in some categories of NMDs (myotonic disorders," exact="myasthenia gravis," post="Lambertâ€&quot;Eaton myasthenic syndrome, spinal muscular atrophy, polymyositis, and immune-mediated"/>
 <result pre="categories of NMDs (myotonic disorders, myasthenia gravis, Lambertâ€&quot;Eaton myasthenic syndrome," exact="spinal muscular atrophy," post="polymyositis, and immune-mediated neuropathies) that present impaired production of"/>
 <result pre="of NMDs (myotonic disorders, myasthenia gravis, Lambertâ€&quot;Eaton myasthenic syndrome, spinal" exact="muscular atrophy," post="polymyositis, and immune-mediated neuropathies) that present impaired production of"/>
 <result pre="and, in many countries, compassionate use for patients with severe" exact="disease" post="has been approved (Table 3). Table 3 Experimental treatments"/>
 <result pre="been approved (Table 3). Table 3 Experimental treatments for SARS-CoV-2" exact="infection" post="Drug Results so far Potential NMD-relevant side effects Chloroquine"/>
 <result pre="Open label studies of HCQâ€‰+â€‰azithromycin found an increased rate of" exact="viral" post="load reduction or disappearance and clinical amelioration in most"/>
 <result pre="toxicity [62] QTc interval prolongation, favoring fatal arrhythmias, such as" exact="ventricular tachycardia" post="and torsade de pointes, especially when combined with other"/>
 <result pre="SSC alone QTc interval prolongation, favoring fatal arrhythmias, such as" exact="ventricular tachycardia" post="and torsade de pointes, especially when combined with other"/>
 <result pre="especially when combined with other QTc-prolonging drugs Risk of toxic" exact="myopathy" post="in association with statins Remdesivir 61 patients with severe"/>
 <result pre="Azithromycin Open label studies of HCQâ€‰+â€‰azithromycin found increased rate of" exact="viral" post="load reduction or disappearance and clinical amelioration in most"/>
 <result pre="CRP C-reactive protein, ECZ eculizumab, HCQ hydroxychloroquine, LPV/RTV lopinavir/ritonavir, MG" exact="myasthenia gravis," post="SSC standard supportive care, TCZ tociluzumab Chloroquine (CQ) and"/>
 <result pre="developed as antimalarial drugs; nowadays, they are used also for" exact="chronic" post="rheumatic diseases, such as systemic lupus erythematosus (SLE) and"/>
 <result pre="as antimalarial drugs; nowadays, they are used also for chronic" exact="rheumatic" post="diseases, such as systemic lupus erythematosus (SLE) and rheumatoid"/>
 <result pre="they are used also for chronic rheumatic diseases, such as" exact="systemic" post="lupus erythematosus (SLE) and rheumatoid arthritis (AR). These drugs"/>
 <result pre="are used also for chronic rheumatic diseases, such as systemic" exact="lupus erythematosus" post="(SLE) and rheumatoid arthritis (AR). These drugs also show"/>
 <result pre="chronic rheumatic diseases, such as systemic lupus erythematosus (SLE) and" exact="rheumatoid arthritis" post="(AR). These drugs also show antiviral activity [69], and"/>
 <result pre="rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid" exact="arthritis" post="(AR). These drugs also show antiviral activity [69], and"/>
 <result pre="compared to standard supportive care in patients with severe COVID-19" exact="pneumonia" post="[76], but other studies are currently ongoing (www.clinicaltrials.gov). Remdesivir"/>
 <result pre="already be altered in NMD patients, such as individuals with" exact="myotonic dystrophy" post="[86]. The Canadian Heart Rhythm Society has released guidelines"/>
 <result pre="patients, such as individuals with myotonic dystrophy [86]. The Canadian" exact="Heart" post="Rhythm Society has released guidelines to minimize the risk"/>
 <result pre="increase and, in long-term treatments, with the development of toxic" exact="neuropathy" post="and myopathy [64, 87]. Furthermore, reports describe drug-induced myopathies"/>
 <result pre="and, in long-term treatments, with the development of toxic neuropathy" exact="and myopathy" post="[64, 87]. Furthermore, reports describe drug-induced myopathies and rhabdomyolysis"/>
 <result pre="in long-term treatments, with the development of toxic neuropathy and" exact="myopathy" post="[64, 87]. Furthermore, reports describe drug-induced myopathies and rhabdomyolysis"/>
 <result pre="and myopathy [64, 87]. Furthermore, reports describe drug-induced myopathies and" exact="rhabdomyolysis" post="in patients treated concomitantly with LPV/RTV and statins [88,"/>
 <result pre="have the potential to cause the onset or worsening of" exact="myasthenia gravis," post="and thus use in these patients should be carefully"/>
 <result pre="may lead to serious toxicity [38]. Treating the underlying NMD" exact="disease" post="in SARS-CoV-2 patients may be challenging. One report describes"/>
 <result pre="case with ETI experienced an MG crisis involving the proximal" exact="upper" post="and lower extremities [47]. This patient was treated with"/>
 <result pre="ETI experienced an MG crisis involving the proximal upper and" exact="lower" post="extremities [47]. This patient was treated with prednisone (increased"/>
 <result pre="days). Due to a worsening of the proximal weakness of" exact="upper" post="and lower limbs, another course of IVIg (650Â mg/kg"/>
 <result pre="to a worsening of the proximal weakness of upper and" exact="lower" post="limbs, another course of IVIg (650Â mg/kg for two"/>
 <result pre="was favourable. Overall, the literature on NMD patients with SARS-CoV-2" exact="infection" post="is limited in number and general considerations are difficult."/>
 <result pre="Overall, the literature on NMD patients with SARS-CoV-2 infection is" exact="limited" post="in number and general considerations are difficult. Best management"/>
 <result pre="neuromuscular disordersNeurology202010.1212/WNL.000000000000956632788244 7.World Health Organization (2020) Clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus (nCoV) infection is suspected:"/>
 <result pre="disordersNeurology202010.1212/WNL.000000000000956632788244 7.World Health Organization (2020) Clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus (nCoV) infection is suspected: interim"/>
 <result pre="7.World Health Organization (2020) Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected: interim guidance."/>
 <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected: interim guidance. https://apps-who-int.pros.lib.unimi.it:2050/iris/handle/10665/330854. Accessed 26 Apr 2020"/>
 <result pre="is suspected: interim guidance. https://apps-who-int.pros.lib.unimi.it:2050/iris/handle/10665/330854. Accessed 26 Apr 2020 8.World" exact="Muscle" post="Society (2020) Covid-19 and people with neuromuscular disorders: World"/>
 <result pre="Muscle Society (2020) Covid-19 and people with neuromuscular disorders: World" exact="Muscle" post="Society position and advice. https://www.worldmusclesociety.org/news/view/150 9.Muscular Distrophy Canada (2020)"/>
 <result pre="a genetic perspectiveOrphanet J Rare Dis201510.1186/s13023-015-0264-325929793 11.JosephRMHunterALRayDWDixonWGSystemic glucocorticoid therapy and" exact="adrenal insufficiency" post="in adults: a systematic reviewSemin Arthritis Rheum20164613314127105755 12.ArmitageRNellumsLBThe COVID-19"/>
 <result pre="glucocorticoid therapy and adrenal insufficiency in adults: a systematic reviewSemin" exact="Arthritis" post="Rheum20164613314127105755 12.ArmitageRNellumsLBThe COVID-19 response must be disability inclusiveLancet Public"/>
 <result pre="of BergamoN Engl J Med2020382e7132369276 14.TwuS-JChenT-JChenC-JOlsenSJLeeL-TFiskTet al.Control measures for severe" exact="acute" post="respiratory syndrome (SARS) in TaiwanEmerg Infect Dis2003971872012781013 15.PulvirentiFCinettoFMilitoCBonanniLPesceAMLeodoriGet al.Health-related"/>
 <result pre="BergamoN Engl J Med2020382e7132369276 14.TwuS-JChenT-JChenC-JOlsenSJLeeL-TFiskTet al.Control measures for severe acute" exact="respiratory" post="syndrome (SARS) in TaiwanEmerg Infect Dis2003971872012781013 15.PulvirentiFCinettoFMilitoCBonanniLPesceAMLeodoriGet al.Health-related quality"/>
 <result pre="Engl J Med2020382e7132369276 14.TwuS-JChenT-JChenC-JOlsenSJLeeL-TFiskTet al.Control measures for severe acute respiratory" exact="syndrome" post="(SARS) in TaiwanEmerg Infect Dis2003971872012781013 15.PulvirentiFCinettoFMilitoCBonanniLPesceAMLeodoriGet al.Health-related quality of"/>
 <result pre="in TaiwanEmerg Infect Dis2003971872012781013 15.PulvirentiFCinettoFMilitoCBonanniLPesceAMLeodoriGet al.Health-related quality of life in" exact="common variable immunodeficiency" post="Italian patients switched to remote assistance during the COVID-19"/>
 <result pre="Infect Dis2003971872012781013 15.PulvirentiFCinettoFMilitoCBonanniLPesceAMLeodoriGet al.Health-related quality of life in common variable" exact="immunodeficiency" post="Italian patients switched to remote assistance during the COVID-19"/>
 <result pre="Clin Immunol202010.1016/j.jaip.2020.04.00332169379 16.MaoLJinHWangMHuYChenSHeQet al.Neurologic manifestations of hospitalized patients with coronavirus" exact="disease" post="2019 in Wuhan, ChinaJAMA Neurol201910.1001/jamaneurol.2020.1127 17.Toscano G, Palmerini F,"/>
 <result pre="Ruiz L, Invernizzi P, Cuzzoni MG, et al. (2020) Guillainâ€&quot;BarrÃ©" exact="syndrome" post="associated with SARS-CoV-2. N Engl J Med 382(26):2574â€&quot;2576. 10.1056/NEJMc2009191"/>
 <result pre="associated with SARS-CoV-2. N Engl J Med 382(26):2574â€&quot;2576. 10.1056/NEJMc2009191 18.ZhaoHShenDZhouHLiuJChenSGuillain-BarrÃ©" exact="syndrome" post="associated with SARS-CoV-2 infection: causality or coincidence?Lancet Neurol202010.1016/S1474-4422(20)30109-532246917 19.TsaiL-KHsiehS-TChaoC-CChenY-CLinY-HChangS-Cet"/>
 <result pre="infection: causality or coincidence?Lancet Neurol202010.1016/S1474-4422(20)30109-532246917 19.TsaiL-KHsiehS-TChaoC-CChenY-CLinY-HChangS-Cet al.Neuromuscular disorders in severe" exact="acute" post="respiratory syndromeArch Neurol2004611669167315534177 20.GrossmanSNHanSCBalcerLJKurzweilAWeinbergHGalettaSLet al.Rapid implementation of virtual neurology"/>
 <result pre="causality or coincidence?Lancet Neurol202010.1016/S1474-4422(20)30109-532246917 19.TsaiL-KHsiehS-TChaoC-CChenY-CLinY-HChangS-Cet al.Neuromuscular disorders in severe acute" exact="respiratory" post="syndromeArch Neurol2004611669167315534177 20.GrossmanSNHanSCBalcerLJKurzweilAWeinbergHGalettaSLet al.Rapid implementation of virtual neurology in"/>
 <result pre="disordersMuscle Nerve20185847548529510449 22.Hatcher-MartinJMAdamsJLAndersonERBoveRBurrusTMChehrenamaMet al.Telemedicine in neurologyNeurology2020943031801829 23.DavisLEColemanJHarnarJKingMKTeleneurology: successful delivery of" exact="chronic" post="neurologic care to 354 patients living remotely in a"/>
 <result pre="Clinic: feasibility and acceptabilityAmyotroph Lateral Scler Frontotemporal Degener20171855556128678542 25.PulleyMTBrittainRHodgesWFrazierCMillerLMatyjasik-LiggettMet al.Multidisciplinary" exact="amyotrophic lateral sclerosis" post="telemedicine care: the store and forward methodMuscle Nerve201959343929802746 26.Van"/>
 <result pre="feasibility and acceptabilityAmyotroph Lateral Scler Frontotemporal Degener20171855556128678542 25.PulleyMTBrittainRHodgesWFrazierCMillerLMatyjasik-LiggettMet al.Multidisciplinary amyotrophic" exact="lateral sclerosis" post="telemedicine care: the store and forward methodMuscle Nerve201959343929802746 26.Van"/>
 <result pre="life and reduce hospitalization rate?Disabil Health J20181130630928967584 31.WilsonAMOngMKSalibaDJamalNIThe veterans affairs" exact="neuropathy" post="scale: a reliable remote polyneuropathy examFront Neurol201910.3389/fneur.2019.0105032038469 32.WilsonAMJamalNIChengEMInkelasMSalibaDHanssenAet al.Teleneurology"/>
 <result pre="Health J20181130630928967584 31.WilsonAMOngMKSalibaDJamalNIThe veterans affairs neuropathy scale: a reliable remote" exact="polyneuropathy" post="examFront Neurol201910.3389/fneur.2019.0105032038469 32.WilsonAMJamalNIChengEMInkelasMSalibaDHanssenAet al.Teleneurology clinics for polyneuropathy: a pilot"/>
 <result pre="B, Kesselring J, Galea M (2015) Telerehabilitation for persons with" exact="multiple sclerosis." post="Cochrane Database Syst Rev CD010508 34.LevyCESilvermanEJiaHGeissMOmuraDEffects of physical therapy"/>
 <result pre="services across the care continuumBMJ Global Health20205e002670 36.PradaVBelloneESchenoneAGrandisMThe suspected SARS-Cov-2" exact="infection" post="in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value"/>
 <result pre="the COVID-19 outbreakJ Neurol202010.1007/s00415-020-10063-732651671 38.JacobSMuppidiSGuidonAGuptillJHehirMHowardJFet al.Guidance for the management of" exact="myasthenia gravis" post="(MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19"/>
 <result pre="38.JacobSMuppidiSGuidonAGuptillJHehirMHowardJFet al.Guidance for the management of myasthenia gravis (MG) and" exact="Lambert-Eaton myasthenic syndrome" post="(LEMS) during the COVID-19 pandemicJ Neurol Sci202010.1016/j.jns.2020.11680332428758 39.SandersDBWolfeGIBenatarMEvoliAGilhusNEIllaIet al.International"/>
 <result pre="for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic" exact="syndrome" post="(LEMS) during the COVID-19 pandemicJ Neurol Sci202010.1016/j.jns.2020.11680332428758 39.SandersDBWolfeGIBenatarMEvoliAGilhusNEIllaIet al.International"/>
 <result pre="for management of myasthenia gravis: executive summaryNeurology20168741942527358333 40.GableKLGuptillJTAntagonism of the" exact="neonatal" post="Fc receptor as an emerging treatment for myasthenia gravisFront"/>
 <result pre="pandemic outbreak from the French Rare Health Care for Neuromuscular" exact="Diseases" post="NetworkRev Neurol (Paris)202010.1016/j.neurol.2020.04.004 46.Anand P, Slama MCC, Kaku M,"/>
 <result pre="AM, Zhou L, et al. (2020) COVID-19 in patients with" exact="myasthenia gravis." post="Muscle Nerve 62(2):254â€&quot;258. 10.1002/mus.26918 47.DellyFSyedMJLisakRPZutshiDMyasthenic crisis in COVID-19J Neurol"/>
 <result pre="L, et al. (2020) COVID-19 in patients with myasthenia gravis." exact="Muscle" post="Nerve 62(2):254â€&quot;258. 10.1002/mus.26918 47.DellyFSyedMJLisakRPZutshiDMyasthenic crisis in COVID-19J Neurol Sci202041411688832413767"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA2020323106110697042881 51.YangXYuYXuJShuHXiaJLiuHet al.Clinical course and outcomes of"/>
 <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
 <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionAnn Intern Med201416038939724474051 54.Hui DS, Chow BK,"/>
 <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionAnn Intern Med201416038939724474051 54.Hui DS, Chow BK, Lo"/>
 <result pre="al.Exhaled air dispersion during noninvasive ventilation via helmets and a" exact="total" post="facemaskChest20151471336134325392954 56.RaccaFMonginiTWolflerAVianelloACutreraRSorboLDet al.Recommendations for anesthesia and perioperative management of"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
 <result pre="trialJAMA Netw Open20203e208857e20885732339248 63.SilvaJASilvaMBSkareTLChloroquine and QTc intervalClin Exp Rheumatol20072579518078640 64.WasayMWolfeGIHerroldJMBurnsDKBarohnRJChloroquine" exact="myopathy" post="and neuropathy with elevated CSF proteinNeurology199851122612279781573 65.VaranOKucukHTufanAMyasthenia gravis due"/>
 <result pre="Netw Open20203e208857e20885732339248 63.SilvaJASilvaMBSkareTLChloroquine and QTc intervalClin Exp Rheumatol20072579518078640 64.WasayMWolfeGIHerroldJMBurnsDKBarohnRJChloroquine myopathy" exact="and neuropathy" post="with elevated CSF proteinNeurology199851122612279781573 65.VaranOKucukHTufanAMyasthenia gravis due to hydroxychloroquineReumatismo20156784926876193"/>
 <result pre="Open20203e208857e20885732339248 63.SilvaJASilvaMBSkareTLChloroquine and QTc intervalClin Exp Rheumatol20072579518078640 64.WasayMWolfeGIHerroldJMBurnsDKBarohnRJChloroquine myopathy and" exact="neuropathy" post="with elevated CSF proteinNeurology199851122612279781573 65.VaranOKucukHTufanAMyasthenia gravis due to hydroxychloroquineReumatismo20156784926876193"/>
 <result pre="10.1056/NEJMoa2007016 67.MulanguSDoddLEDaveyRTTshiani MbayaOProschanMMukadiDet al.A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN Engl J Med20193812293230331774950 68.DiurnoFNumisFGPortaGCirilloFMaddalunoSRagozzinoAet al.Eculizumab treatment in patients"/>
 <result pre="agentsPNAS198178360536096115382 70.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005211015631631 71.KeyaertsEVijgenLMaesPNeytsJRanstMVIn vitro inhibition of severe acute"/>
 <result pre="coronavirus infection and spreadVirol J2005211015631631 71.KeyaertsEVijgenLMaesPNeytsJRanstMVIn vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun200432326426815351731 72.JieZHeHXiHZhiZMulticenter"/>
 <result pre="infection and spreadVirol J2005211015631631 71.KeyaertsEVijgenLMaesPNeytsJRanstMVIn vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun200432326426815351731 72.JieZHeHXiHZhiZMulticenter collaboration"/>
 <result pre="and spreadVirol J2005211015631631 71.KeyaertsEVijgenLMaesPNeytsJRanstMVIn vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun200432326426815351731 72.JieZHeHXiHZhiZMulticenter collaboration group"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBioScience Trends202014727332074550 75.Molina JM, Delaugerre C, Le"/>
 <result pre="pathwaysJ Immunol20192031021103031263039 79.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with azithromycin for moderate and severe" exact="acute" post="respiratory distress syndrome: a retrospective, propensity score-matching analysis of"/>
 <result pre="Immunol20192031021103031263039 79.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with azithromycin for moderate and severe acute" exact="respiratory" post="distress syndrome: a retrospective, propensity score-matching analysis of prospectively"/>
 <result pre="Agents20185191892429501821 80.McGonagleDSharifKOâ€™ReganABridgewoodCThe role of cytokines including interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like diseaseAutoimmun Rev202016610253710.1016/j.autrev.2020.102537 81.Luo P, Liu"/>
 <result pre="al. (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related" exact="respiratory" post="failure: a case report. Ann Oncol 83.HowardJFUtsugisawaKBenatarMMuraiHBarohnRJIllaIet al.Safety and"/>
 <result pre="and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised" exact="myasthenia gravis" post="(REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyLancet"/>
 <result pre="et al. (2020) Guidance on minimizing risk of drug-induced ventricular" exact="arrhythmia" post="during treatment of COVID-19: a statement from the canadian"/>
 <result pre="arrhythmia during treatment of COVID-19: a statement from the canadian" exact="heart" post="rhythm society. Can J Cardiol 36(6):948â€&quot;951. 10.1016/j.cjca.2020.04.003 86.ParkKMShinKJKimSEParkJHaSYKimBJProlonged corrected"/>
 <result pre="Cardiol 36(6):948â€&quot;951. 10.1016/j.cjca.2020.04.003 86.ParkKMShinKJKimSEParkJHaSYKimBJProlonged corrected QT interval in patients with" exact="myotonic dystrophy" post="type 1J Clin Neurol2013918619123894242 87.PurohitVPChloroquine neuromyotoxicityAm J Med1988843 Pt"/>
 <result pre="10.1016/j.cjca.2020.04.003 86.ParkKMShinKJKimSEParkJHaSYKimBJProlonged corrected QT interval in patients with myotonic dystrophy" exact="type 1J" post="Clin Neurol2013918619123894242 87.PurohitVPChloroquine neuromyotoxicityAm J Med1988843 Pt 15683348265 88.Mah"/>
 <result pre="Clin Neurol2013918619123894242 87.PurohitVPChloroquine neuromyotoxicityAm J Med1988843 Pt 15683348265 88.Mah MingJBGillMJDrug-induced" exact="rhabdomyolysis" post="after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in"/>
 <result pre="treated with rosuvastatin and lopinavir/ritonavirAntivir Ther (Lond)20111643543721555828 90.GummiRRKukulkaNADerocheCBGovindarajanRFactors associated with" exact="acute" post="exacerbations of myasthenia gravisMuscle Nerve20196069369931469909"/>
</results>
